AU3351293A - Piperidineacetic acid derivatives as inhibitors of fibrinogen-dependent blood platelet aggregation - Google Patents

Piperidineacetic acid derivatives as inhibitors of fibrinogen-dependent blood platelet aggregation

Info

Publication number
AU3351293A
AU3351293A AU33512/93A AU3351293A AU3351293A AU 3351293 A AU3351293 A AU 3351293A AU 33512/93 A AU33512/93 A AU 33512/93A AU 3351293 A AU3351293 A AU 3351293A AU 3351293 A AU3351293 A AU 3351293A
Authority
AU
Australia
Prior art keywords
fibrinogen
inhibitors
acid derivatives
platelet aggregation
blood platelet
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU33512/93A
Inventor
Colin David Eldred
Brian David Judkins
Henry Anderson Kelly
Barry Porter
James Russell Wheatcroft
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929201171A external-priority patent/GB9201171D0/en
Priority claimed from GB929206004A external-priority patent/GB9206004D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AU3351293A publication Critical patent/AU3351293A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
AU33512/93A 1992-01-21 1993-01-15 Piperidineacetic acid derivatives as inhibitors of fibrinogen-dependent blood platelet aggregation Abandoned AU3351293A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB929201171A GB9201171D0 (en) 1992-01-21 1992-01-21 Chemical compounds
GB9201171 1992-01-21
GB929206004A GB9206004D0 (en) 1992-03-19 1992-03-19 Chemical compounds
GB9206004 1992-03-19

Publications (1)

Publication Number Publication Date
AU3351293A true AU3351293A (en) 1993-08-03

Family

ID=26300182

Family Applications (1)

Application Number Title Priority Date Filing Date
AU33512/93A Abandoned AU3351293A (en) 1992-01-21 1993-01-15 Piperidineacetic acid derivatives as inhibitors of fibrinogen-dependent blood platelet aggregation

Country Status (7)

Country Link
EP (1) EP0623120A1 (en)
JP (1) JPH07503459A (en)
CN (1) CN1077953A (en)
AU (1) AU3351293A (en)
IL (1) IL104446A0 (en)
MX (1) MX9300256A (en)
WO (1) WO1993014077A1 (en)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZW4194A1 (en) * 1993-03-29 1994-12-21 Zeneca Ltd Heterocyclic compounds
US5753659A (en) * 1993-03-29 1998-05-19 Zeneca Limited Heterocyclic compouds
US5652242A (en) * 1993-03-29 1997-07-29 Zeneca Limited Heterocyclic derivatives
DK0691959T3 (en) * 1993-03-29 1999-04-26 Zeneca Ltd Heterocyclic derivatives as platelet aggregation inhibitors
US5750754A (en) * 1993-03-29 1998-05-12 Zeneca Limited Heterocyclic compounds
US5463011A (en) * 1993-06-28 1995-10-31 Zeneca Limited Acid derivatives
GB9313285D0 (en) * 1993-06-28 1993-08-11 Zeneca Ltd Acid derivatives
GB9313268D0 (en) * 1993-06-28 1993-08-11 Zeneca Ltd Chemical compounds
USRE39263E1 (en) * 1994-05-04 2006-09-05 Bayer Aktiengesellschaft Substituted aromatic thiocarboxylic acid amides and their use as herbicides
WO1995030661A1 (en) 1994-05-04 1995-11-16 Bayer Aktiengesellschaft Substituted aromatic thiocarboxylic acid amides and their use as herbicides
IL116893A (en) * 1995-02-10 2000-02-29 Yamanouchi Pharma Co Ltd Piperazine derivatives and pharmaceutical compositions containing them
WO1996024583A1 (en) * 1995-02-10 1996-08-15 Yamanouchi Pharmaceutical Co., Ltd. Novel benzamidine derivatives and medicinal composition thereof
WO1997002245A1 (en) * 1995-07-06 1997-01-23 Japan Tobacco Inc. Benzamidoxime derivatives and medicinal use thereof
DE19524765A1 (en) * 1995-07-07 1997-01-09 Boehringer Mannheim Gmbh New oxazolidinone derivatives, processes for their preparation and medicaments containing these compounds
TR199801961T2 (en) * 1996-03-30 1999-01-18 Boehringer Mannheim Gmbh New oxalidine derivatives, processes for their production, and pharmaceuticals containing these compounds.
NZ334389A (en) * 1996-08-28 2001-05-25 Ube Industries Cyclic amine derivatives
DE19652919A1 (en) * 1996-12-19 1998-06-25 Solvay Pharm Gmbh Piperazinophenyl and piperazinophenyloxycarboxylic acid derivatives and processes and intermediates for their preparation and pharmaceuticals containing these compounds
AR013693A1 (en) * 1997-10-23 2001-01-10 Uriach & Cia Sa J NEW PIPERIDINES AND PIPERAZINAS AS INHIBITORS OF THE PLAQUETARY AGREGATION
HU225741B1 (en) * 1998-02-27 2007-07-30 Ube Industries Cyclic amino compounds, use of them for producing pharmaceutical compositions and pharmaceutical compositions containing them
AU2004229418B2 (en) * 2003-04-15 2008-07-31 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
AU2005286793A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-CoA desaturase enzymes
AU2005286647A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
BRPI0515482A (en) 2004-09-20 2008-07-22 Xenon Pharmaceuticals Inc heterocyclic derivatives and their uses as therapeutic agents
TW200626138A (en) 2004-09-20 2006-08-01 Xenon Pharmaceuticals Inc Heterocyclic derivatives and their use as therapeutic agents
EP1799668A1 (en) 2004-09-20 2007-06-27 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-coa desaturase
TW200626155A (en) 2004-09-20 2006-08-01 Xenon Pharmaceuticals Inc Heterocyclic derivatives and their use as therapeutic agents
CA2580856A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
MX2007009946A (en) * 2005-02-16 2007-09-26 Schering Corp Pyridyl and phenyl substituted piperazine-piperidines with cxcr3 antagonist activity.
JP2008530220A (en) 2005-02-16 2008-08-07 シェーリング コーポレイション Pyrazinyl-substituted piperazine-piperidine having CXCR3 antagonist activity
WO2006088836A2 (en) * 2005-02-16 2006-08-24 Schering Corporation Piperazine-piperidines with cxcr3 antagonist activity
KR20070107040A (en) * 2005-02-16 2007-11-06 쉐링 코포레이션 Heteroaryl substituted pyrazinyl-piperazine-piperidlnes with cxcr3 antagonist activity
AU2006214480A1 (en) 2005-02-16 2006-08-24 Pharmacopeia, Inc. Novel heterocyclic substituted pyridine or phenyl compounds with CXCR3 antagonist activity
MX2007009945A (en) * 2005-02-16 2007-09-26 Schering Corp Heterocyclic substituted piperazines with cxcr3 antagonist activity.
CA2618646A1 (en) 2005-06-03 2007-11-15 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
WO2007053436A1 (en) 2005-10-31 2007-05-10 Janssen Pharmaceutica N.V. Substituted piperazines and piperidines as modulators of the neuropeptide y2 receptor
WO2010081851A1 (en) 2009-01-14 2010-07-22 Genoscience Pharma Piperidin-4-ylpiperazine compounds for the treatment of hcv infection
US9738604B2 (en) 2010-09-03 2017-08-22 Duke University Ethynylbenzene derivatives
CA2921427A1 (en) 2013-08-16 2015-02-19 Duke University Substituted hydroxamic acid compounds
WO2015024016A2 (en) * 2013-08-16 2015-02-19 Duke University 2-piperidinyl substituted n,3-dihydroxybutanamides
WO2015024021A2 (en) 2013-08-16 2015-02-19 Duke University Antibacterial compounds
CA3054792A1 (en) 2017-02-28 2018-09-07 Morphic Therapeutic, Inc. Inhibitors of .alpha.v.beta.6 integrin
CN110573499B (en) 2017-02-28 2023-04-21 莫菲克医疗股份有限公司 Inhibitors of αvβ6 integrin
PE20211640A1 (en) 2018-08-29 2021-08-24 Morphic Therapeutic Inc INHIBITION OF INTEGRIN xvß6
CN113075343B (en) * 2020-01-04 2024-02-23 东莞市东阳光仿制药研发有限公司 Hydroxylamine and detection method of hydroxylamine salt

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2500825B1 (en) * 1981-02-27 1985-08-23 Torii & Co Ltd NOVEL SUBSTITUTED 4-AMIDINO-PHENYL CARBOXYLATE, PREPARATION METHOD THEREOF AND ANTI-COMPLEMENT AGENT COMPRISING SAME
US4433152A (en) * 1981-05-25 1984-02-21 Nippon Chemiphar Co., Ltd. Amidinopiperidine derivatives
PT84171B (en) * 1986-01-24 1989-03-30 Sanofi Sa A process for the preparation of derivatives of alpha-arylsulfonylamininoacyl-β-aminophenylalanineamides, as well as their synergistic derivatives and pharmaceutical compositions containing them
GB9122016D0 (en) * 1991-10-16 1991-11-27 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
IL104446A0 (en) 1993-05-13
MX9300256A (en) 1993-07-01
JPH07503459A (en) 1995-04-13
WO1993014077A1 (en) 1993-07-22
CN1077953A (en) 1993-11-03
EP0623120A1 (en) 1994-11-09

Similar Documents

Publication Publication Date Title
AU3351293A (en) Piperidineacetic acid derivatives as inhibitors of fibrinogen-dependent blood platelet aggregation
EP0542363A3 (en) Piperidineacetic acid derivatives as inhibitors of fibrinogen-dependent blood platelet aggregation
AU2689292A (en) Cyclohexaneacetic acid derivatives as inhibitors of fibrinogen-dependent blood platelet aggregation
AU6375196A (en) New inhibitors of platelet aggregation
AU4041293A (en) Phenylderivate as inhibitors of atp citrate lyase
IL86464A (en) 4-phosphinyl-3- hydroxybutanoic acid derivatives useful as cholesterol biosynthesis inhibitors and pharmaceutical compositions containing the same
AU4936890A (en) Medicament containing dihydrolipoic acid as active substance
AU635415B2 (en) Use of n-alkyl-lactams as crystallization inhibitors
AU567236B2 (en) Pharmaceutical formulation of tissue plasminogen activator
AU3020595A (en) Use of substituted 4-phenyl-6-amino-nicotinic acid derivatives as medicaments
AU3098189A (en) Methods and compositions for inhibiting platelet aggregation
AU4533793A (en) Phenyl amidine urea derivatives as platelet aggregation inhibitors
AU6302596A (en) Piperidineacetic acid derivatives as inhibitors of fibrinoge n-dependent blood platelet aggregation
AU3040589A (en) Homoarginine-based peptides as platelet aggregation inhibitors
AU1875988A (en) 5-aralkyl-2-mercaptoimidazole derivatives as dopamine-beta- hydroxylase inhibitors
AU5906986A (en) Ascorbic acid for treatment of sino-nasal congestion
AU4801493A (en) New derivatives of neuraminic acid
AU3506293A (en) Method of inhibiting the aggregation of blood platelets
ZA888880B (en) The use of anellated compounds as inhibitors of ertyhrocyte aggregation
AU586306B2 (en) Method for inhibiting post-surgical adhesion formation by the topical administration of tissue plasminogen activator
AU2296792A (en) Novel inhibitors of platelet aggregation
AU6180486A (en) Novel tissue plasminogen activator derivatives
AU4540693A (en) Phenyl amidine alkanoic acids and lactones useful as platelet aggregation inhibitors
AU6267894A (en) N-acyl beta amino acid derivatives useful as platelet aggregation inhibitors
AU3494293A (en) Thiazolyl-pyridine derivatives and their use as gastric acid secretion inhibitors